TeraRecon Cardiovascular.Calcification.CT vs iCAC Device
AI Verdict
Choose TeraRecon Cardiovascular.Calcification.CT if…
Choose TeraRecon Cardiovascular.Calcification.CT if your clinical workflow demands a comprehensive AI solution for detailed cardiac CT analysis, including advanced plaque characterization, vessel segmentation, and functional assessment. This tool is ideal for specialized cardiology departments requiring robust 3D segmentation, zero-click centerline creation, and support for pre-operative planning beyond basic calcium scoring.
View TeraRecon Cardiovascular.Calcification.CT →Choose iCAC Device if…
Choose Bunkerhill Health's iCAC Device if your institution aims to opportunistically screen for coronary artery calcium from routine, non-contrast, non-gated chest CT scans already acquired for other purposes. This tool is best suited for integrating into existing imaging workflows to provide adjunctive CAC information to radiologists, facilitating early cardiovascular disease detection from readily available data.
View iCAC Device →When choosing between TeraRecon Cardiovascular.Calcification.CT and Bunkerhill Health’s iCAC Device, physicians should consider their primary use case and existing infrastructure. TeraRecon’s tool is best suited for comprehensive cardiac CT analysis, offering detailed 3D segmentation of calcified plaques, support for various calcium scoring methods (Agatston, volume, mean mass), and integration into a broader cardiac package that includes zero-click centerline creation, vessel analysis, and cardiac structure segmentation. This makes it ideal for cardiologists and cardiothoracic surgeons requiring in-depth pre-operative evaluation and functional analysis.
The key practical difference lies in their scope and input requirements. TeraRecon’s solution is designed for dedicated cardiac CT scans, providing a rich set of features for detailed cardiac assessment. In contrast, Bunkerhill Health’s iCAC Device excels at opportunistic screening, analyzing routine, non-contrast, non-gated chest CT scans to detect and quantify coronary artery calcium. This makes iCAC particularly valuable for radiologists seeking to leverage existing CT data for early cardiovascular disease detection without requiring specialized cardiac imaging protocols.
Therefore, a physician focused on comprehensive cardiac imaging and detailed pre-operative planning would likely find TeraRecon Cardiovascular.Calcification.CT more aligned with their needs. Conversely, a physician or radiology department aiming to broadly screen for cardiovascular risk using readily available non-cardiac CT scans, and integrate those findings into EHRs, would benefit more from Bunkerhill Health’s iCAC Device.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | TeraRecon Cardiovascular.Calcification.CT | iCAC Device |
|---|---|---|
| Pricing | Subscription-based | Contact for pricing |
| Deployment | Containerized application (SaMD), also available as SaaS within Eureka Clinical AI platform. | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TeraRecon Cardiovascular.Calcification.CTTool A emphasizes a 'near-zero-click post-processing user experience' and a 'clinician-centric design' with intuitive workflows, which are strong indicators of ease of use for its core imaging analysis functions. While Tool B's Carebricks platform offers innovative conversational AI for patient records, Tool A's specific features for automated image segmentation and centerline creation suggest a more streamlined workflow for the direct task of cardiac CT analysis.
Clinical Value
iCAC DeviceBoth tools are FDA-cleared for CAC detection and quantification, offering significant clinical utility. However, Tool B's strength lies in its 'opportunistic identification' of CAC from routine, non-cardiac CT scans, which has a broader public health impact by detecting cardiovascular disease in previously undiagnosed patients. Furthermore, Bunkerhill Health has secured CMS reimbursement for its AI algorithms for CAC and AVC analysis, solidifying its pathway for real-world clinical adoption and value.
Pricing & Value
iCAC DeviceTool A offers transparent, subscription-based pricing with a single annual fee, providing budget predictability. While Tool B's pricing details require direct contact, its recent achievement of CMS reimbursement for its AI algorithms for CAC and AVC analysis significantly enhances its value proposition. This reimbursement pathway provides a clear financial incentive for healthcare providers, making Tool B a more valuable investment in the long term.
Enterprise Readiness
TeraRecon Cardiovascular.Calcification.CTTool A explicitly states 'Yes' for BAA and HIPAA compliance in its published specifications, providing immediate assurance for enterprise deployments. It is also available as SaaS within the Eureka Clinical AI platform, designed for interoperability. While Tool B's Carebricks platform is HIPAA compliant and deployed at major health systems, Tool A's upfront transparency regarding these critical compliance aspects gives it a slight edge.
Innovation
iCAC DeviceBoth tools leverage AI for advanced imaging analysis. Tool A offers innovative 'zero-click' features and is part of an open AI platform. However, Tool B's 'opportunistic identification' of CAC from routine CT scans represents a paradigm shift in early disease detection and population health screening. Additionally, Bunkerhill Health's development of a foundation model and conversational AI for patient records demonstrates a broader, forward-looking approach to AI innovation in healthcare.
Support & Docs
TeraRecon Cardiovascular.Calcification.CTTool A provides a well-defined support structure, including multiple contact methods (phone, email, 24-hour emergency line), tiered support, and readily accessible user manuals both online and within the software. Tool B offers a general contact email and form but lacks the detailed, multi-channel support and explicit documentation resources that TeraRecon clearly outlines.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | TeraRecon Cardiovascular.Calcification.CT | iCAC Device |
|---|---|---|
| Name | TeraRecon Cardiovascular.Calcification.CT | iCAC Device |
| Company | Terarecon | Bunkerhill Health |
| Description (Purpose) | AI-powered software as a medical device (SaMD) that analyzes CT images to automatically detect and measure calcifications in the coronary arteries, providing a mask for calcium scoring systems. | FDA-cleared AI algorithm that detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. |
| Core Calcification Analysis | Automatic 3D segmentation of calcified plaques in coronary arteries; outputs mask for calcium scoring systems. | Detects and quantifies coronary artery calcium (CAC); outputs visual representation of estimated CAC segmentation. |
| Supported Measurements | Agatston score, volume, mean mass (mg) measurements. | Exact and four-category quantitative estimates of CAC burden in Agatston units. |
Videos
Demos, reviews, and walkthroughs featuring TeraRecon Cardiovascular.Calcification.CT and iCAC Device.